TY - JOUR
T1 - Upregulation of cytosolic phosphoenolpyruvate carboxykinase is a critical metabolic event in melanoma cells that repopulate tumors
AU - Li, Yong
AU - Luo, Shunqun
AU - Ma, Ruihua
AU - Liu, Jing
AU - Xu, Pingwei
AU - Zhang, Huafeng
AU - Tang, Ke
AU - Ma, Jingwei
AU - Zhang, Yi
AU - Liang, Xiaoyu
AU - Sun, Yanling
AU - Ji, Tiantian
AU - Wang, Ning
AU - Huang, Bo
N1 - Publisher Copyright:
©2015 AACR.
PY - 2015/4/1
Y1 - 2015/4/1
N2 - Although metabolic defects have been investigated extensively in differentiated tumor cells, much less attention has been directed to the metabolic properties of stem-like cells that repopulate tumors [tumor-repopulating cells (TRC)]. Here, we show that melanoma TRCs cultured in three-dimensional soft fibrin gels reprogram glucose metabolism by hijacking the cytosolic enzyme phosphoenolpyruvate carboxykinase (PCK1), a key player in gluconeogenesis. Surprisingly, upregulated PCK1 in TRCs did not mediate gluconeogenesis but promoted glucose side-branch metabolism, including in the serine and glycerol-3-phosphate pathways. Moreover, this retrograde glucose carbon flow strengthened rather than antagonized glycolysis and glucose consumption. Silencing PCK1 or inhibiting its enzymatic activity slowed the growth of TRCs in vitro and impeded tumorigenesis in vivo. Overall, our work unveiled metabolic features of TRCs in melanoma that have implications for targeting a unique aspect of this disease.
AB - Although metabolic defects have been investigated extensively in differentiated tumor cells, much less attention has been directed to the metabolic properties of stem-like cells that repopulate tumors [tumor-repopulating cells (TRC)]. Here, we show that melanoma TRCs cultured in three-dimensional soft fibrin gels reprogram glucose metabolism by hijacking the cytosolic enzyme phosphoenolpyruvate carboxykinase (PCK1), a key player in gluconeogenesis. Surprisingly, upregulated PCK1 in TRCs did not mediate gluconeogenesis but promoted glucose side-branch metabolism, including in the serine and glycerol-3-phosphate pathways. Moreover, this retrograde glucose carbon flow strengthened rather than antagonized glycolysis and glucose consumption. Silencing PCK1 or inhibiting its enzymatic activity slowed the growth of TRCs in vitro and impeded tumorigenesis in vivo. Overall, our work unveiled metabolic features of TRCs in melanoma that have implications for targeting a unique aspect of this disease.
UR - http://www.scopus.com/inward/record.url?scp=84941657247&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84941657247&partnerID=8YFLogxK
U2 - 10.1158/0008-5472.CAN-14-2615
DO - 10.1158/0008-5472.CAN-14-2615
M3 - Article
C2 - 25712344
AN - SCOPUS:84941657247
SN - 0008-5472
VL - 75
SP - 1191
EP - 1196
JO - Cancer Research
JF - Cancer Research
IS - 7
ER -